Ryan Deschner
Stock Analyst at Raymond James
(4.77)
# 577
Out of 4,630 analysts
68
Total ratings
67.8%
Success rate
41.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintained: Buy | $27 → $40 | $18.51 | +116.10% | 6 | Aug 7, 2026 | |
| ACOG Alpha Cognition | Initiated Coverage: Buy | $20 | $9.13 | +119.06% | 1 | Jul 10, 2026 | |
| TVRD Tvardi Therapeutics | Upgraded: Buy | $10 | $1.87 | +434.76% | 5 | Jul 8, 2026 | |
| ACHV Achieve Life Sciences | Initiated Coverage: Buy | $20 | $6.65 | +200.75% | 1 | Jun 26, 2026 | |
| PRQR ProQR Therapeutics | Maintained: Buy | $14 → $10 | $1.88 | +433.33% | 2 | Jun 26, 2026 | |
| VKTX Viking Therapeutics | Maintained: Buy | n/a | $34.26 | - | 2 | Jun 24, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | n/a | $32.89 | - | 6 | Jun 24, 2026 | |
| DNTH Dianthus Therapeutics | Maintained: Buy | n/a | $108.92 | - | 5 | Jun 12, 2026 | |
| ADMA ADMA Biologics | Initiated Coverage: Buy | $21 | $9.90 | +112.12% | 1 | Jun 10, 2026 | |
| LQDA Liquidia | Maintained: Buy | n/a | $90.22 | - | 12 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $1.84 | +389.13% | 4 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $110 → $165 | $100.65 | +63.93% | 4 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $23 | $13.25 | +73.58% | 2 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $6.16 | - | 11 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $54 → $143 | $157.77 | -9.36% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 → $12 | $4.00 | n/a | 4 | Aug 5, 2025 |
Trevi Therapeutics
Aug 7, 2026
Maintained: Buy
Price Target: $27 → $40
Current: $18.51
Upside: +116.10%
Alpha Cognition
Jul 10, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $9.13
Upside: +119.06%
Tvardi Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $10
Current: $1.87
Upside: +434.76%
Achieve Life Sciences
Jun 26, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $6.65
Upside: +200.75%
ProQR Therapeutics
Jun 26, 2026
Maintained: Buy
Price Target: $14 → $10
Current: $1.88
Upside: +433.33%
Viking Therapeutics
Jun 24, 2026
Maintained: Buy
Price Target: n/a
Current: $34.26
Upside: -
Vera Therapeutics
Jun 24, 2026
Maintained: Buy
Price Target: n/a
Current: $32.89
Upside: -
Dianthus Therapeutics
Jun 12, 2026
Maintained: Buy
Price Target: n/a
Current: $108.92
Upside: -
ADMA Biologics
Jun 10, 2026
Initiated Coverage: Buy
Price Target: $21
Current: $9.90
Upside: +112.12%
Liquidia
Jun 4, 2026
Maintained: Buy
Price Target: n/a
Current: $90.22
Upside: -
May 13, 2026
Maintained: Buy
Price Target: $9
Current: $1.84
Upside: +389.13%
May 7, 2026
Maintained: Buy
Price Target: $110 → $165
Current: $100.65
Upside: +63.93%
Mar 13, 2026
Upgraded: Buy
Price Target: $23
Current: $13.25
Upside: +73.58%
Jan 9, 2026
Maintained: Buy
Price Target: n/a
Current: $6.16
Upside: -
Nov 19, 2025
Upgraded: Buy
Price Target: $54 → $143
Current: $157.77
Upside: -9.36%
Aug 5, 2025
Maintained: Buy
Price Target: $11 → $12
Current: $4.00
Upside: n/a